Daily Stock Analysis, CBAY, CymaBay Therapeutics Inc, priceseries

CymaBay Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.80
Close
4.19
High
4.33
Low
3.79
Previous Close
3.81
Daily Price Gain
0.38
YTD High
4.44
YTD High Date
Mar 16, 2017
YTD Low
1.46
YTD Low Date
Jan 23, 2017
YTD Price Change
2.29
YTD Gain
120.53%
52 Week High
4.44
52 Week High Date
Mar 16, 2017
52 Week Low
1.15
52 Week Low Date
Nov 9, 2016
52 Week Price Change
2.75
52 Week Gain
190.97%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 18. 2014
8.24
Jan 14. 2015
9.86
17 Trading Days
19.71%
Link
LONG
Jan 30. 2015
10.00
Feb 24. 2015
11.76
16 Trading Days
17.60%
Link
LONG
Jul 14. 2015
2.81
Jul 15. 2015
2.97
1 Trading Days
5.69%
Link
LONG
Dec 16. 2015
1.44
Dec 29. 2015
1.57
8 Trading Days
8.96%
Link
LONG
Feb 12. 2016
1.06
Mar 2. 2016
1.15
12 Trading Days
8.77%
Link
LONG
Mar 11. 2016
1.25
Mar 18. 2016
1.36
5 Trading Days
9.00%
Link
LONG
Apr 18. 2016
1.69
May 4. 2016
2.52
12 Trading Days
49.38%
Link
LONG
Aug 12. 2016
1.94
Sep 1. 2016
2.25
14 Trading Days
16.03%
Link
LONG
Nov 10. 2016
1.53
Nov 25. 2016
1.81
10 Trading Days
18.33%
Link
LONG
Jan 3. 2017
1.90
Jan 12. 2017
2.02
7 Trading Days
6.58%
Link
LONG
Feb 7. 2017
2.05
Mar 21. 2017
3.97
29 Trading Days
93.65%
Link
Company Information
Stock Symbol
CBAY
Exchange
NasdaqCM
Company URL
http://www.cymabay.com
Company Phone
510-293-8800
CEO
Harold E. van Wart
Headquarters
California
Business Address
7999 GATEWAY BLVD, SUITE 130, NEWARK, CA 94560
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001042074
About

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary chol...

Description

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.